Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 8:45 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 11,247 matching trials from the live ClinicalTrials.gov search.
Conditions
Maternal Morbidity, Antenatal Health, Neonatal Morbidity, Retention in Care, Prenatal Care
Interventions
Patient Navigation Program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
1 Day to 2 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Wrinkles, Fine Lines, Crepey Skin, Acne Scars, Active Acne, Enlarged Pores, Loose Skin
Interventions
RF Device (Potenza™)
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Hollywood, California
Terminated Phase 2 Interventional Results available

Panhematin for Prevention of Acute Attacks of Porphyria

NCT02922413
Conditions
Acute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria
Interventions
Hemin for injection, Placebo
Biological · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Ovarian Cancer, Breast Cancer, Prostate Cancer
Interventions
LY2606368
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria
Interventions
Rifampin
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Interventions
patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
La Mesa, California • Orange, California • Denver, Colorado + 9 more
Conditions
Congenital Myasthenic Syndrome
Interventions
AlloEx exosomes
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Naples, Florida
Conditions
Retinitis Pigmentosa.
Interventions
Retinal transplantation instrument, Fetal tissue.
Device
Lead sponsor
Radtke, Norman D., M.D.
Individual
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Sickle Cell Disease (SCD)
Interventions
crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more
Completed No phase listed Observational Accepts healthy volunteers

Decision Support for Parents Receiving Information About Child's Rare Disease

NCT01875640
Conditions
Disorder of Sex Development, Intersex Conditions, Congenital Adrenal Hyperplasia, Hypospadias
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Conditions
Pompe Disease
Interventions
alglucosidase alfa
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • Durham, North Carolina • Hershey, Pennsylvania + 3 more
Conditions
Infant, Newborn, Disease, Pain, Retinopathy of Prematurity, Eye Diseases
Interventions
phototherapy eye shield
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 1 Year
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Epilepsy, Epilepsy, Temporal Lobe, Seizures
Interventions
anteromesial temporal resection, antiepileptic drugs
Procedure · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 9 more
Conditions
Fuchs Dystrophy
Interventions
This is an observational study. There is no therapeutic intervention.
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
55 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Sickle Cell Anemia
Interventions
beet juice (Unbeetable)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
19 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Interventions
Placebo, Lumasiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more
Conditions
Atopic Dermatitis
Interventions
topical desonide hydrogel 0.05%
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Ichthyosis, Pruritus
Interventions
Avena Sativa Skincare Regimen
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Microcurrent Stimulation to Treat Macular Degeneration

NCT01790958
Conditions
Retinal Diseases, Stargardt's Disease, Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
4
States / cities
Hilo, Hawaii • Honolulu, Hawaii • Kahului, Hawaii + 1 more
Completed Phase 2 Interventional Results available

Vitamin D to Prevent Autism in Newborn Siblings

NCT01366885
Conditions
Autistic Disorder
Interventions
Vitamin D3
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
20 Years to 44 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Oregon City, Oregon
Conditions
Brain Diseases, Metabolic, Inborn, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders
Interventions
Not listed
Lead sponsor
Andrea Gropman
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 9 more
Completed Not applicable Interventional Accepts healthy volunteers

Fetal Pillow Randomized Controlled Trial

NCT03342508
Conditions
Labor Complication
Interventions
Fetal Pillow
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts